Safety and target engagement profile of two oxaloacetate doses in Alzheimer’s patients

INTRODUCTION: Brain bioenergetics are defective in Alzheimer’s disease (AD). Preclinical studies find oxaloacetate (OAA) enhances bioenergetics, but human safety and target engagement data are lacking. METHODS: We orally administered 500 or 1000 mg OAA, twice daily for 1 month, to AD participants (n...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Alzheimers Dement
Main Authors: Vidoni, Eric D., Choi, In-Young, Lee, Phil, Reed, Gregory, Zhang, Na, Pleen, Joseph, Mahnken, Jonathan D., Clutton, Jonathan, Becker, Annette, Sherry, Erica, Bothwell, Rebecca, Anderson, Heidi, Harris, Robert A., Brooks, William, Wilkins, Heather M., Mosconi, Lisa, Burns, Jeffrey M., Swerdlow, Russell H.
Formato: Artigo
Idioma:Inglês
Publicado: 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8084114/
https://ncbi.nlm.nih.gov/pubmed/32715609
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/alz.12156
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares